Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CEFEPIME Cause Malignant neoplasm progression? 16 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Malignant neoplasm progression have been filed in association with CEFEPIME (Cefepime). This represents 0.3% of all adverse event reports for CEFEPIME.

16
Reports of Malignant neoplasm progression with CEFEPIME
0.3%
of all CEFEPIME reports
14
Deaths
12
Hospitalizations

How Dangerous Is Malignant neoplasm progression From CEFEPIME?

Of the 16 reports, 14 (87.5%) resulted in death, 12 (75.0%) required hospitalization, and 3 (18.8%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CEFEPIME. However, 16 reports have been filed with the FAERS database.

What Other Side Effects Does CEFEPIME Cause?

Drug ineffective (864) Acute kidney injury (706) Off label use (383) Encephalopathy (376) Drug reaction with eosinophilia and systemic symptoms (288) Condition aggravated (242) Confusional state (207) Rash (194) Pyrexia (185) Thrombocytopenia (181)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which CEFEPIME Alternatives Have Lower Malignant neoplasm progression Risk?

CEFEPIME vs CEFEPIME\CEFEPIME CEFEPIME vs CEFIDEROCOL CEFEPIME vs CEFIXIME CEFEPIME vs CEFMETAZOLE CEFEPIME vs CEFOPERAZONE

Related Pages

CEFEPIME Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression CEFEPIME Demographics